Preliminary findings showed varying binding affinities across cancer cell lines for EGFR-binding A, C, and P peptides (Han et al. 2013; Zhou et al. 2019; Williams et al. 2020; Wang et al. 2021; Li et al. 2024): A peptide bound best to TNBC cells (Han et al. 2013; Zhou et al. 2019; Williams et al. 2020); unpublished data), P peptide showed higher affinity in head and neck cancer cells (Wang et al. 2021), and C peptide excelled in pancreatic cancer cells (Li et al. 2024). This evidence concerns the gene EGFR and head and neck cancer.